Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A

BACKGROUND: This Phase 1/2a study evaluated the safety, immunogenicity, and efficacy of an experimental malaria vaccine comprised of the recombinant Plasmodium falciparum protein apical membrane antigen-1 (AMA-1) representing the 3D7 allele formulated with either the AS01B or AS02A Adjuvant Systems....

Descripción completa

Detalles Bibliográficos
Autores principales: Spring, Michele D., Cummings, James F., Ockenhouse, Christian F., Dutta, Sheetij, Reidler, Randall, Angov, Evelina, Bergmann-Leitner, Elke, Stewart, V. Ann, Bittner, Stacey, Juompan, Laure, Kortepeter, Mark G., Nielsen, Robin, Krzych, Urszula, Tierney, Ev, Ware, Lisa A., Dowler, Megan, Hermsen, Cornelus C., Sauerwein, Robert W., de Vlas, Sake J., Ofori-Anyinam, Opokua, Lanar, David E., Williams, Jack L., Kester, Kent E., Tucker, Kathryn, Shi, Meng, Malkin, Elissa, Long, Carole, Diggs, Carter L., Soisson, Lorraine, Dubois, Marie-Claude, Ballou, W. Ripley, Cohen, Joe, Heppner, D. Gray
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669163/
https://www.ncbi.nlm.nih.gov/pubmed/19390585
http://dx.doi.org/10.1371/journal.pone.0005254

Ejemplares similares

Ejemplares similares